Expansion of the clinical trial infrastructure to accelerate subject enrollment has been completed. IRB approvals obtained for six new facilities, bringing total participating sites to 16. No impact on the 2027 fiscal year results.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4591","jir_company_name":"Ribomic Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4591-20260824-01.pdf","jir_short_summary":"Expansion of the clinical trial infrastructure to accelerate subject enrollment has been completed. IRB approvals obtained for six new facilities, bringing total participating sites to 16. No impact on the 2027 fiscal year results.","jir_summary":"### Section Heading\nThis release is IR information reporting the expansion of the clinical trial conduct framework for umedaptanib pegol, a treatment for achondroplasia, in the domestic Phase 3 trial. Six additional facilities have obtained approval from the Institutional Review Board (IRB), bringing the total number of implementing medical institutions to 16, thereby strengthening the enrollment acceleration foundation. Consequently, the planned system setup has been completed as scheduled, and accelerated progress is expected going forward. It is stated that there will be no impact on the full-year results for the fiscal year ending March 2027.\n\n### Section 2 Heading\nUmedaptanib pegol is an aptamer that inhibits FGF2, and development of a new drug that directly acts on the pathogenesis of achondroplasia is progressing. It has been designated as a drug for rare diseases, offering a long-term treatment option. The expansion of the trial framework is an important milestone to accelerate subject enrollment, and future trial progress along with safety and efficacy data will be of interest to investors.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#NoShareRepurchaseMentioned, #Dividend, #EarningsInformation, #Personnel & Organization, #ClinicalTrials","jir_key_figures":"Subject enrollment-capable facilities: cumulative 16 facilities\nNew IRB-approved facilities due to expansion of trial conduct framework: 6 facilities\nImpact on full-year results for the fiscal year ending March 2027: Unknown \u2192 'No impact' (as described in the text)","jir_meta_title":"Ribomic Announces Domestic Phase III Trial Infrastructure Expansion for Achondroplasia Drug | August 2026","jir_meta_description":"Ribomic announces expansion of clinical trial sites for UMedaptanib pegol in the domestic Phase III trial. IRB approvals obtained for six new facilities, strengthening patient enrollment. No impact on 2027 fiscal year results.","jir_og_title":"[Ribomic] Announces Expanded Trial Conduct Infrastructure | August 2026","jir_og_description":"Expansion of facilities for the domestic Phase III trial in UMIN has prepared for subject enrollment, with heightened anticipation for trial progress. No financial impact.","jir_og_image_url":"\/assets\/og\/company-product_announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":60243,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-106320","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n